On May 15, 2025 Agendia, Inc., reported that new data on its comprehensive genomic tests will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (ASCO) (Free ASCO Whitepaper), taking place May 30th – June 3rd, 2025, in Chicago, Illinois (Press release, Agendia, MAY 15, 2025, View Source [SID1234653200]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The selected abstracts draw upon data from the ongoing FLEX Study (NCT03053193), which recently reached a significant milestone of 20,000 enrolled patients, nearly 10,000 of which have reached 3-year follow-up and 4,000 have reached 5-year follow-up. This real-world evidence study is providing critical insights into how genomic testing can address disparities in early-stage breast cancer care and optimize treatment selection across diverse patient populations. Since its launch in April 2017, the FLEX Study has enrolled patients across 100 sites in the U.S. and around the world, including 12 NCI-designated cancer centers, and has conducted over 40 sub-studies in several topics.

"The 2025 ASCO (Free ASCO Whitepaper) Annual Meeting provides an important platform to share our latest findings from the FLEX Study, which now includes crucial survival metrics for a modern cohort of early-stage breast cancer patients," said William Audeh, MD, MS, Chief Medical Officer at Agendia. "The exceptional follow-up rates enable meaningful analysis of correlations between patient-reported genetic ancestry, molecular classifications, and treatment approaches, reinforcing the value of genomic testing in guiding equitable treatment decisions."

The following are details of the abstracts that have been accepted as poster presentations:

Association of MammaPrint and clinical outcomes by race among 5000 individuals with HR+HER2- early-stage breast cancer enrolled in FLEX
Author: Cobain, E., et al.
Presenter: Erin Cobain MD, Associate Professor in the Division of Hematology/Oncology at the University of Michigan Medical School, Ann Arbor and co-Principal Investigator of the SWOG S2206 Trial
Session: Quality Care/Health Services Research
Date / Time: Saturday, May 31, 2025 | 1:30 – 4:30 PM CDT

Real-World Evidence from FLEX: Utility of MammaPrint in guiding treatment planning for patients aged 70 and older with early-stage breast cancer
Author: Mahtani, R., et al.
Presenter: Reshma Mahtani, DO, Baptist Health Miami Cancer Institute, Chief of Breast Medical Oncology at Baptist Health Wellness and Medical Complex
Session: Quality Care/Health Services Research
Date / Time: Saturday, May 31, 2025 | 1:30 – 4:30 PM CDT

Association of ImPrintTN signature with survival outcomes by race in Basal-Type Triple Negative Breast Cancer (TNBC)
Author: Sharma, P., et al.
Presenter: Priyanka Sharma, MD, Professor, Medical Oncology, University of Kansas Medical Center
Session: Breast Cancer – Local/Regional/Adjuvant
Date / Time: Monday, June 2, 2025 | 9:00 AM – 12:00 PM CDT

Molecular Insights into HR+/HER2+ Early-Stage Breast Cancer: Neoadjuvant Therapy Responses by MammaPrint and BluePrint genomic subtypes
Author: Samijan, L., et al.
Presenter: Adam Brufsky, MD, PhD, Professor and Associate Chief of Hematology and Oncology at UPMC Hillman Cancer Center
Session: Breast Cancer – Local/Regional/Adjuvant
Date / Time: Monday, June 2, 2025 | 9:00 AM – 12:00 PM CDT
More information about the program can be found at the 2025 ASCO (Free ASCO Whitepaper) Annual Meeting website.